{"id":"switch-twice-daily-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Twice-daily insulin regimens typically combine intermediate-acting or long-acting insulin (basal) with rapid-acting insulin (bolus) to mimic physiologic insulin secretion. This approach addresses both fasting glucose levels and postprandial glucose excursions in patients with type 1 or type 2 diabetes who require insulin therapy.","oneSentence":"Insulin replacement therapy that provides basal and bolus glucose control through twice-daily subcutaneous injections to manage blood glucose in diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:27.832Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus requiring insulin therapy"}]},"trialDetails":[{"nctId":"NCT05614089","phase":"PHASE4","title":"Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","status":"COMPLETED","sponsor":"Jing Luo","startDate":"2023-03-15","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes","enrollment":400},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT06072963","phase":"PHASE2","title":"COMMETS- Combination MCI Metabolic Syndrome","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2024-01-30","conditions":"Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome","enrollment":80},{"nctId":"NCT03862690","phase":"","title":"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01835431","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-10-17","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":362},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT01892020","phase":"PHASE4","title":"Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":161},{"nctId":"NCT01092806","phase":"PHASE4","title":"Insulin Secretion and Advagraf","status":"COMPLETED","sponsor":"University of Oslo School of Pharmacy","startDate":"2009-10","conditions":"Post Transplant Diabetes Mellitus","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NovoMix® 30 Penfill®, lantus®, levemir®, NovoRapid®"],"phase":"marketed","status":"active","brandName":"switch twice-daily insulin","genericName":"switch twice-daily insulin","companyName":"Mackay Memorial Hospital","companyId":"mackay-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin replacement therapy that provides basal and bolus glucose control through twice-daily subcutaneous injections to manage blood glucose in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}